Close menu




March 17th, 2021 | 07:25 CET

Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends

  • Healthcare
Photo credits: pixabay.com

The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.

time to read: 3 minutes | Author: Nico Popp
ISIN: DE0005785604 , SG2E73981531 , DE000SHL1006

Table of contents:


    Fresenius: Solid but no more

    Fresenius is a Company based in Bad Homburg, Germany, that has dedicated itself entirely to dialysis. When patients suffer kidney failure, this form of blood washing using technical equipment is often the only way to bridge the time until a transplant. The dialysis business accounts for about 50% of sales, artificial nutrition for another 20% and the hospital Company Helios for more than 25%. The hospital services business accounts for about 5%. Fresenius' figures have recently been mediocre: although sales have increased, profits have been lackluster.

    Moreover, the share price has been flat for 3 months: the bottom line is a loss of 5.6%. Although Fresenius, focusing on dialysis and its other pillars, is a potential beneficiary of rising healthcare system expenditures, the word is not yet out in the market. Investors who invest for the long term and can tolerate a fair amount of boredom in their portfolio see Fresenius as a dividend stock: around 2.3% yield beckons in this way.

    Q&M Dental: The Asian dividend stock with growth fantasy

    Q&M Dental is also a dividend stock. The penny stock from Singapore is only a small company at first glance. The operator of 5 dental clinics and 114 practices took an early stake in a manufacturer of corona tests last year and is working with official agencies in Singapore, among others, on the application of these tests, and has put out feelers in other countries. The combination of dental treatments and corona tests seems to be a profitable business for Q&M. In addition to the strong financials, the Company announced a special dividend in early March, in addition to its regular dividend. Overall, the stock brings a dividend yield of around 5% to all investors who have been shareholders in recent weeks.

    In addition to its bread-and-butter business of dental treatments, Q&M Dental also sees itself as an innovative company and aims to score points with artificial intelligence in everyday dental practice. The franchise system for dental practices is to be further expanded. Given the success of recent years, it is evident that this will succeed: many dentists seem to feel extremely comfortable under the Q&M umbrella. Since the Company is not only active in Singapore, the share offers investors a comprehensive Asian fantasy and adds to that the test kit business, which Q&M is expected to do for some time to come. The stock has been kissed awake in recent weeks but is still trading under the radar of many investors.

    Siemens Healthineers: Surprises loom here

    By contrast, the Siemens Healthineers share is much better known. The Company offers equipment related to imaging and diagnostics. Last year, many examinations were postponed or canceled altogether due to the pandemic. As a result, Siemens Healthineers' figures at the end of last year were not so rosy either. But the Company took countermeasures and launched a share buyback last fall. Most recently, Siemens Healthineers announced a stable dividend and thus convinced the market of its merits. Many investors believe that the preventive medical checkup business will return to robust growth in the future. The stock has climbed 14% in the past 3 months and looks promising from a chart perspective. It should only be a matter of time before the share rises above EUR 50.

    After that, it will be necessary for Siemens Healthineers to be able to surprise the market. Given the sluggish vaccination business in Germany, it cannot be ruled out that business in the first two quarters of 2021 will again be somewhat less good. The share price could then also run out of steam. Investors who want to sit out this phase can still buy the stock. Those who like it more dynamic should take a closer look at Q&M. Here, Covid-19 fantasy meets a proven business with dental treatments, which is also to be further expanded. Q&M Dental Group's recent dividend could set the tone for the future.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on March 13th, 2025 | 07:00 CET

    Big Pharma's billion-dollar markets under pressure – NetraMark as the key for Bayer and Novo Nordisk?

    • Healthcare
    • healthtech
    • Biotechnology
    • Pharma
    • AI
    • hightech

    In 2025, the pharmaceutical market faces significant challenges, including rising costs and regulatory hurdles. In this environment, companies like NetraMark, Bayer, and Novo Nordisk could make a significant difference through innovative solutions and strategic partnerships. NetraMark, a Canadian HealthTech company, is revolutionizing clinical trials with AI technology, which could be particularly beneficial in the areas of research into active ingredients for the central nervous system and in oncology. These are currently the biggest dropouts in industry. NetraMark's technology could increase the efficiency of drug development and open up new opportunities for investors. Bayer is focusing on targeted therapies in precision oncology and has a promising drug in development that specifically targets an overarching mutation in various cancers. Novo Nordisk is cementing its reputation as an innovator in the fight against chronic obesity, particularly with its successor to the obesity drug CagriSema. The Phase III REDEFINE 2 study achieved its primary objective, although the results fell short of high expectations. A closer look is now warranted.

    Read

    Commented by Stefan Feulner on January 27th, 2025 | 07:20 CET

    Novo Nordisk, Desert Gold Ventures, Palantir – AI madness, Trump fuels the gold rush

    • Mining
    • Gold
    • Software
    • Healthcare

    Things have been moving at a rapid pace since the old and new President of the United States, Donald Trump, took office. Around 80 decrees were signed on the first working day alone. One of the Republican's goals is to make the US the "global hub for crypto and artificial intelligence". With the commitment of over USD 500 billion for the largest AI project in history, the industry is likely to face further appreciation. The price of gold has also increased, and it is now approaching the magic mark of USD 3,000 per ounce. In this context, producers and exploration companies are now likely to tap into their catch-up potential.

    Read

    Commented by Juliane Zielonka on November 28th, 2024 | 07:15 CET

    Barrick Gold, Desert Gold, Novo Nordisk - How political decisions and market opportunities drive prices

    • Mining
    • Gold
    • Healthcare

    The capital markets are again demonstrating how closely intertwined political decisions, external market factors, and entrepreneurial skills are. The planned expansion of Medicare and Medicaid coverage of obesity drugs could open up new growth prospects for the Danish pharmaceutical giant Novo Nordisk in the US. However, the wind of change is blowing in the direction of a new administration with a strong reputation in the US healthcare sector. Industry giant Barrick Gold shines with impressive numbers, with operating cash flow alone at USD 23 billion. Meanwhile, explorer Desert Gold is securing fresh capital through clever financing for its promising SMSZ gold project in Mali, Africa. Here is what investors should be looking out for now.

    Read